Approximately two million new cases of human immunodeficiency virus (HIV) infection occur every year. Adhering to a pre-exposure prophylaxis therapy(PrEP) allows patients to reduce their risk of transmission by about 90%, but adherence to the therapy can vary a great deal. This presentation evaluates the utilization of two PrEP therapies, emtricitabine/tenofovir disoproxil fumarate (Truvada®) and emtricitabine/tenofovir alafenamide (Descovy®), among a MassHealth population.
Analysis of Pre-Exposure Prophylaxis Utilization in a Medicaid Population
Monday, May 10, 2021